COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study - 07/06/24
, Pinsolle Julian b, Bizieux-Thaminy Acya c, Schneider Sophie d, Godbert Benoît e, Portel Laurent f, Francois Hugues g, Dayen Charles h, Obert Julie i, Dujon Cécile j, Dumont Patrick k, Julien Sylvie l, Meyer Nicolas m, Letierce Alexia n, Morel Hugues o, Debieuvre Didier pOn behalf of the Study Group KBP-2020-CPHG
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | The incidence of COVID-19 was higher in former smokers, specific histological subgroups, PS score ≥2 vs 0- and in stages III-IV vs I-II patients. |
• | In our cohort, the incidence COVID-19 was lower in active smokers, compared to former smokers and the chemotherapy had no impact. |
• | In 2020, COVID-19 had a major impact on mortality of LC patients with the risk of death being more than four times that of the population non-COVID-19. |
Summary |
Background |
COVID-19 started to spread early in 2020, the precise year that lung cancer (LC) patients were recruited into the prospective epidemiological cohort KBP-2020-CPHG in French hospitals. This provides a unique opportunity to study COVID-19 incidence, survival risk factors, and overall prognosis.
Methods |
COVID data was collected before vaccination was made available. Clinical characteristics were compared (COVID vs non-COVID), incidence rate ratios were calculated based on clinical characteristics, survival (1 and 3 months) was estimated and the impact of COVID-19 on the overall prognosis of the cohort was studied.
Results |
In 2020, 285 out of 8,999 lung cancer patients were diagnosed with COVID-19. Diagnosis was mainly based on PCR tests (86.3 %). The annual incidence was 8.3 % (95 % CI [7.4, 9.3]); it was higher in former smokers and patients with squamous cell carcinoma or small cell carcinoma than in those with adenocarcinoma, in those with a PS score ≥2 versus 0–1, and with stages III-IV versus stages I-II. The incidence was reduced in patients who received chemotherapy or immunotherapy. 64.9 % of patients were hospitalized due to COVID-19. Risk factors for death at 1 and 3 months in COVID-19 patients were age, LC stage, and PS score. Multivariate analysis showed a major prognostic impact of COVID-19 on mortality of LC patients (hazard ratio: 4.12, 95 % CI [3.42, 4.97], p < 0.001).
Conclusions |
This prospective study demonstrated the high incidence of COVID-19 in LC patients and identified as risk factors for COVID-19: smoking status, histology, PS, and stage. The impact of COVID-19 on lung cancer mortality appears major.
Le texte complet de cet article est disponible en PDF.Keywords : Lung cancer, Covid, Mortality, Stages
Plan
Vol 86
Article 101093- novembre 2024 Retour au numéro
Article précédent
- Interstitial pneumonia with auto-immune features (IPAF): Is a change of criteria necessary?
- Raphael Borie, Joshua J Solomon
- The intermittent intrapulmonary deflation technique for airway clearance in patients with cystic fibrosis: A randomized trial
- Juliana Ribeiro Fonseca Franco de Macedo, Anne-Sophie Aubriot, Gregory Reychler, Morgane Penelle, Sophie Gohy, William Poncin
Bienvenue sur EM-consulte, la référence des professionnels de santé.